Over a year ago, a new camera stunned the world with its ability to snap 10 trillion frames per second. That speed made it ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

This project pioneers ‘Phase Imaging’ that visualizes the phase information of quantum beams (X-rays, neutrons, electrons, and so on) passing through objects. Phase imaging is different from ...

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

Bayer offers a leading portfolio of contrast media for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), along with devices for their precise administration, informatics ...

GE HealthCare has announced positive results from a Phase I study of its manganese-based macrocyclic magnetic resonance imaging (MRI) contrast agent. Data from the first-in-human trial ...

Among over 6,300 women who completed supplementary imaging, the cancer detection rate per 1,000 examinations was 17.4 for abbreviated MRI, 4.2 for ABUS, and 19.2 for contrast-enhanced mammography ...

Bayer is on the brink of filing a new MRI contrast agent for approval that can reduce levels of gadolinium, a rare earth metal that can have health and environmental consequences. The company has ...

Barium contrast media plays an essential role in gastrointestinal imaging, offering a reliable, radiopaque medium with favorable safety and cost profiles compared to iodinated agents.

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

CHALFONT ST GILES, England, October 07, 2024--GE HealthCare Announces Phase I Results for a First-of-its-Kind Macrocyclic Manganese-Based MRI Contrast Agent ...